All News

Dealing with the challenges of health and wellness after cancer treatment is tricky enough, but managing it in the midst of the COVID-19 pandemic is an even bigger obstacle. One survivor details how she tries to take it one wellness win at a time.

“Being a caregiver is a role that is defined by cancer more so than it is by the caregiver.”

The Food and Drug Administration approved the combination of Opdivo and Yervoy with 2 cycles of chemotherapy as a first-line treatment for certain patients with metastatic non-small cell lung cancer.

Chemotherapy killed my veins, and quarterly blood tests won't let me forget that. How it's impossible to ever forget the changes cancer brings.

One cancer survivor details protecting the story of other survivors from those who would sensationalize it.

A cancer survivor describes the changes of going for treatment during the pandemic.

During Skin Cancer Awareness Month, one melanoma survivor reflects on her treatment and the preventive measures everyone should take to avoid skin cancer.

The Food and Drug Administration approved Alunbrig for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Receiving a cancer diagnosis is scary enough, but amid the COVID-19 pandemic it has even more challenges. But cancer survivors can help ease their worries by listening and sharing their experiences.

The Food and Drug Administration’s approval of the PARP inhibitor Lynparza for patients with metastatic prostate cancer gives a smaller subgroup of patients another treatment option if hormonal therapies do not work.

“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”

Vitamin D is vital for anyone, but for people with cancer it can be especially vital even during social distancing rules.

The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.

The Food and Drug Administration continues to approve cancer therapies amid the COVID-19 pandemic. Here are five approvals that patients with cancer may have missed.

It's not just time spent sitting in the lobby. Waiting is a way of life for people with cancer.

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

The Food and Drug Administration gave the green light to the PARP inhibitor Lynparza for men with metastatic castration-resistant prostate cancer that has a defective DNA-repair process and has progressed after treatment with the novel hormone-controlling drugs Xtandi (enzalutamide) or Zytiga (abiraterone acetate).

The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.

Do parts of being in a pandemic feel familiar to you? Yet you have never been in one before? One cancer survivor suggests that's because those who have been on the cancer journey have experienced this before.

Tecentriq is approved as an initial treatment for non-small cell lung cancer that has spread and expresses the protein PD-L1 but does not have alterations in the EGFR or ALK genes.

Precision medicine is improving outcomes for aggressive types of lymphomas, such as mantle cell lymphoma.

COVID-19 has dramatically altered the lives of millions across the globe, but for patients with cancer, the new restrictions and new challenges are ones they have already managed to handle.

Cancer changes us, and often we find new parts of ourselves that help us accomplish new goals in the face of adversity and tragedy.

Cancer changes one’s life in ways both big and small. One, in particular, is how it changes one's relationship with food. So, CURE asked its audience how cancer changed their relationship with food and how they handle nutrition moving forward.

A breast cancer survivor celebrates her 10-year "cancerversary" during the global pandemic and finds ways to feel grateful.

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.

Velcade not only delays the progression of mantle cell lymphoma when given after stem cell transplant but also prolongs survival. However, the treatment comes with significant side effects.

The Food and Drug Administration has approved the combination of Opdivo-Yervoy immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer that do not have certain genomic tumor aberrations.